Study aims and goal: This study will evaluate the safety, biomarker effects and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington’s disease.
No. of study participants and sites: This phase II study aims to recruit participants from approximately 70 sites in Argentina, Australia, Austria, Canada, Denmark, France, Germany, Italy, New Zealand, Poland, Spain, Switzerland, the UK and the US.
For further information see the clinical trial registration.